STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
Despite all the setbacks, Boston Scientific won’t stop pushing the Watchman.
Key points
- Continue to STAT+ to read the full story….
When that approval finally came through, for a limited pool of patients, Boston Scientific was prepared with a plan for something much larger.
The medical-device giant committed hundreds of millions to acquire the tiny heart implant more than a decade ago, and then endured a years-long debate at the Food and Drug Administration over whether to approve it.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.